+34 679 490 537info@nanbiosis.com

News U2

News U2

Five experts explain the results of the CSIC Global Health Platform after a year of research on the SARS-CoV-2 coronavirus

Margarita del Val, Pilar Marco, Mario Mellado, Diego Ramiro and Iñaki Comas will disseminate, in a webinar through YouTube, the works on the disease, diagnosis and social impact
– The platform investigates the new coronavirus in six areas: prevention, disease, containment and diagnosis, treatment and vaccines, social impact and communication

Five experts from the Higher Council for Scientific Research (CSIC) will explain in a webinar broadcast on YouTube, on Wednesday, May 5 at 6:00 p.m., the results of a year of research at the CSIC on the SARS-CoV-2 coronavirus carried out by the Global Health Platform. In the session, titled El CSIC y la covid-19. A year later, five coordinators of the platform will participate: the virologist and immunologist Margarita del Val, from the Severo Ochoa Molecular Biology Center (CBMSO-CSIC-UAM), who will moderate the debate; the nanobiotechnologist Pilar Marco, who leads the group Nb4D of CIBER-BBN/IQAC-CSIC and Scientific Director of NANBIOSIS unit 2Custom Antibody Service (CAbS); the demographer Diego Ramiro, from the Institute of Economics, Geography and Demography (IEGD-CSIC), the immunologist Mario Mellado, director of the National Center for Biotechnology (CNB-CSIC), and the biologist Iñaki Comas, from the Institute of Biomedicine of Valencia (IBV -CSIC). Interested parties may ask questions via email webinar@csic.es or live through the chat on the CSIC Comunicación YouTube channel.
The CSIC Global Health Platform, launched in March 2020, coordinates more than 100 projects to unravel the new coronavirus and seek medium and long-term solutions. The platform has mobilized and coordinates more than 300 research groups from more than 90 CSIC centers, out of a total of 120, in six work topics, which try to cover all aspects of the pandemic with an interdisciplinary approach: prevention, prevention, disease, containment and diagnosis, treatment and vaccines, social impact, and communication.
The platform has coordinated 100 research projects and actions, ranging from the development of antivirals and anti-inflammatory treatments, the monitoring of transmission, the study of the virus genome and the impact of mutations, the genetics of patients, their immune response to infection and vaccination, up to the launch of systems for diagnosis and containment of the virus.
The platform has also included studies carried out on the social perception of the measures, especially on the impact on nursing homes.

The Global Health platform has become a stable structure for scientific cooperation, as well as for the generation of patented technologies. Its consolidation, reinforcing its structure and coordination mechanisms, in particular the link with the clinical sector, prepares the body to face new challenges and opportunities, and for the development of initiatives with companies in Spain, necessary to configure a response to this and future pandemics.


The speakers
Margarita del Val (CBM-CSIC-UAM) is a virologist and immunologist. She coordinates the CSIC Global Health Platform, where she directs a project to characterize the immune response to infection by the SARS-CoV-2 virus and to vaccination.
Pilar Marco (IQAC-CSIC) is a nanobiotechnologist. She runs a project (POC4COV) to develop rapid detection tests for the coronavirus. The objective is to obtain low-cost tests to detect biomarkers of the virus using electrochemical technology and nanostructures.
Mario Mellado (CNB-CSIC) is an immunologist and directs the CSIC’s National Center for Biotechnology, which has become the agency’s center on research into treatments for the SARS-CoV-2 coronavirus. At the CNB-CSIC, two vaccine prototypes for covid-19 and treatments with monoclonal antibodies are being developed, and drugs with possible efficacy to treat the new coronavirus are being screened.
Diego Ramiro (IEGD-CSIC) is a demographer and directs three projects to assess the impact of the covid-19 pandemic on residences for the elderly.
Iñaki Comas (IBV-CSIC) is a biologist and an expert in genomics. He co-leads a genomic epidemiology project on the evolution of SARS-CoV-2 in Spain. His team has observed that there were multiple introductions of SARS-CoV-2 in Spain, but that only a few caused a large number of infections.

Source of information: CSIC

Read More

A GLOBAL VISION OF THE COVID-19 PANDEMIC by CSIC

A report from the Spanish National Research Council (CSIC) collects in open access the results of a year of research on SARS-CoV-2. The book ‘A global vision of the COVID-19 pandemic’ shows the responses and solutions obtained by the 300 research teams of the CSIC Global Health Platform. The Institute for Advanced Chemistry of Catalonia (IQAC-CSIC) has participated in the preparation of the chapter ‘Actions in containment and diagnosis’:

Visit CSIC website to read the full news.

Read More

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology.

According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science.

NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribute their bit to Science and highlight their essential role in nowadays research. Especially we want to recognize the work of scientists women involved in NANBIOSIS, whatever is the nature of their contribution: technical, scientific development, management, coordination, direction, etc; just to mention some examples:
Neus Ferrer and Mercedes Márquez in the Scientific Direction and Coordination of Unit 1 Protein Production Platform (PPP)
Pilar Marco and Nuria Pascual in the Management and Scientific Coordination of U2 Custom Antibody Service (CAbS) 
Miriam Royo in the Scientific Direction of U3 Synthesis of Peptides Unit
Nora Ventosa and Nathaly Segovia in the Scientific Direction and Technical Coordination of U6 Biomaterial Processing and Nanostructuring Unit
Isabel Oliveira and Teresa Galán in the Coordination of U7 Nanotecnology Unit
Rosa Villa and Gemma Gabriel in the Management and Scientific Coordination of U8 Micro – Nano Technology Unit
Gema Martínez in the Scientific Coordination of U9 Synthesis of Nanoparticles Unit
Fany Peña in the Scientific Coordination of U13 Tissue & Scaffold Characterization Unit
Mª Luisa González Martín and Margarita Hierro in the of Direction and Scientific Coordination of U16 Tissue & Scaffold Characterization Unit
Gemma Pascual and Isabel Trabado in the Coordination of the U17 Confocal Microscopy Service
Isolda Casanova in the Scientific Coordination of U18 Nanotoxicology Unit
Beatriz Moreno in the Scientific Direction of Unit 19 Clinical tests lab
Ibane Abásolo in the Scientific Coordination of Unit 20 In Vivo Experimental Platformt
Verónica Crisóstomo in the Scientific Direction of Unit 24 Medical Imaging 
Ana Paula Candiota in the Scientific Coordination of Unit 25 Biomedical Applications I 
Maria Luisa García in the Scientific Direction of U28 NanoImaging Unit from Bionand, recently incorporated to NANBIOSIS, Anna Aviñó in the Scientific Coordination of U29 Oligonucleotide Synthesis Platform (OSP) – and

Nerea Argarate in the coordination of NANBIOSIS

Thanks to all of you and your teams!

Read More

NANBIOSIS Unit 2 obtains the Biosafety Level 2 Accreditation

The laboratory of NANBIOSIS Unit 2 from IQAC-CSIC and CIBER-BBN has obtained the biosafety level 2 accreditation, which allows the laboratory to work with biological agents classified in the risk group 2.

Biological containment level 2 (NBS2) laboratories are generally required to work with any derivative of human blood or other primates, body fluids (especially when they are visibly contaminated with blood), cell lines, or tissues in which has uncertainty about the presence of an infectious agent.

Also, the group participates in the COVID project “Point-of-care tests for the rapid detection of SARS-CoV-2 (POC4CoV)”, funded by the CSIC. This project involves the handling of swabs and serum samples from both positive and negative SARS-CoV-2 patients. Lluïsa Vilaplana, member of research group Nb4D of CIBER-BBN and IQAC-CSIC, led by Dra. M. Pilar Marco, wich Coordinates NANBIOSIS U2, has coordinated the process to obtain the accreditation.

The laboratory has an antechamber or clean locker room, a card-controlled entry system and a space for the storage of materials and reagents. It has also an independent air conditioning system, a specific air renewal system and a biosafety cabin type 2A, with HEPA filter. In addition, it is equipped with a suitable lighting system, an emergency lighting system and a large observation peephole on the door.

In addition to this specific equipment, the laboratory is equipped with an inverted microscope, centrifuge, thermostatic bath, stirrers, incubators, refrigerator and autoclave for sterilization and waste management.

The Nanobiotechnology for Diagnosis (Nb4D) research group , focus the research on the development of biomarkers for the diagnosis of infectious diseases. Nowadays, the group participates in five research projects related to this topic. These projects involve working with clinical samples for the detection of the pathogens Pseudomonas aeruginosa (Gram – type bacteria) and Staphylococcus aureus (Gram + type bacteria), both classified in risk group 2.

Source of information: IQAC-CSIC Communication

Read More

Highly sensitive monoclonal antibodies for a new biosensor for hormones detection in fertility treatments

Nb4D research group and NANBIOSIS U2 Custom Antibody Service (CAbS) of CIBER-BBN at the IQAC-CSIC, together with the company Droplite Technologies have obtained a Retos-Collaboration project funded by the Ministry of Science and Innovation, for the development of a biosensor for detection and rapid quantification of hormones, linked to in-vitro fertility treatments.

NANBIOSIS U2 CAbS will be responsible for the production of highly sensitive monoclonal antibodies, counting on the experience in this field of Juan Pablo Salvador, project coordinator, Núria Pascual and Mª Pilar Marco.

The measurement of the hormone estradiol is a key indicator, both of maturity and of the degree of ovarian stimulation, very important in a successful fertilization process. But there are no tools that allow accurate and sensitive monitoring.

Thus, the consortium formed by Nb4D-Droplite proposes as a solution a new device to perform the control and quantification of hormones, in particular estradiol, in less than 30 minutes, without the need for a central laboratory and only using a drop of blood, which is obtained simply by pricking the patient’s finger.

With funding of € 388,531, the project strategy consists of a transversal collaboration between the Droplite company and the CIBER-BBN research center, through the Nb4D group, supported by the Hospital Clínic de Barcelona, ​​which allows a continuous evaluation and optimization of the prototype based on the exchange of experiences and knowledge.

On the other hand, Droplite, led by its co-founders André Guedes and Rafael Porcar, contributes its experience in the development of an optical detection system based on nanotechnology, which will allow to detect and monitor, automatically and quantitatively, different markers and provide results in just 10 minutes. Droplite is dedicated to the biotechnology sector that emerged as a spin-off of the Institute of Photonic Sciences (ICFO)

The call Retos Colaboración

The aid of this call, managed by the Ministry of Science and Innovation and the State Research Agency, aims to support experimental development projects in cooperation between companies and research organizations, in order to promote the development of new technologies, business application of new ideas and techniques, and contribute to the creation of new products and services.

Read More

Nb4D group- NANBIOSIS U2 receives the acreditation TECNICO, in the on line event organizes by ACCIO

Las November 27 was held the ACCIO ceremony (on line this year due to the Covid Pandemic restrictions) of disclosure of new TECNIO accreditations.

Aurea Rodriguez, Director of Business Innovation at ACCIO has welcomed the attendees to the event. Later, the TECNIO program Coordinator, Marta Peidro, presented the background and rationale for this accreditation for excellence groups in technology transfer in Catalonia. This year there have been five new groups from among all Catalan universities and research organizations, which have obtained the TECNIO accreditation for the first time, making a total of fifty-four groups accredited in 2020.

The event continued with the presentation of the five new accredited groups, starting with the IQAC-CSIC – CIBER-BBN Nb4D group, coordinator of NANBIOSIS unit 2 Custom Antibody Service (CAbS) that investigates improvements to current clinical diagnostic methods.

After the presentations of the five new groups, the tools and benefits that ACCIO offers to TECNIO groups were explained and the event ended with a round of questions from the attendees, such as what will be the future financing strategy of ACCIO for TECNIO groups or how has it been the response to the recent call for INNOTEC grants

As expressed by Prof M. Pilar Marco: “This seal recognizes us as a tech-transfer agent with distinguishing technological capabilities and increases our visibility in front of the business world.”

ACCIÓ is the agency set up by the Catalan Government to make Catalan enterprise more competitive throughout the world. Its key aims are to drive innovation, internationalisation and attract inward investment. ACCIÓ is enterprise-centred, working on the needs of each individual business and to work hand in hand to look for opportunities and achieve that all important competitive edge. At ACCIÓ we believe this edge can come about with work on three vital areas of competitive dynamics: innovation, internationalisatio, attraction of investment. ACCIÓ is a proactive agency, with a simple, clear and efficient modus operandi, above all dedicated to working in close quarters with enterprise. ACCIÓ is based in Barcelona with an international network of a further 35 Business Promotion Centres covering some 80 markets worldwide. It provides advice and practical help for businesses with a vocation to expand worldwide. It focuses on attracting inward investment into Catalonia and also works on synergies between R+D+i areas and business.

Read More

Nb4D group – NANBIOSIS Unit 2 CAbS – accredited with the TECNIO seal

The Nb4D group of CIBER-BBN and IQAB-CSIC, coordinator of NANBIOSIS Unit 2 Custom Antibody Service (CAbS), has been accredited with the TECNIO seal.

This accreditation is the hallmark TECNIO granted by the Government of Catalonia, through ACCIÓ, to identify the developers and facilitators of differential technologies in Catalonia. TECNIO is the umbrella brand for catalan technology centres and university research groups dedicated to industrial research and technology transfer.

ACCIOCERTIFICATIONQUALITY MANAGEMENT SYSTEM

Read More

Prof. Pilar Marco, in the program “Meridiano Turing” of RTVE explains the COVID-19 tests.

The last edition of the program “Meridiano Turing” of RTVE interviews Maria Pilar Marco Head of CIBER-BBN and IQAC-CSIC group Nb4D and NANBIOSIS-ICTS Unit 2 Custom Antibody Service (CAbS), Cesar Fernández (Head of the Chemical Transducers Group at IMB-CNM, CSIC) and María Cruz Minguillón (EGAR group at IDAEA)

Pilar Marco y César Fernández, the authors of the block of the CSIC’s report entitled “Containment and diagnosis“, explain wich is the best way to diagnose COVID and how reliable are the tests in this moment.

What is needed is to detect an infection -says Pilar Marco- is viral material and we have two types of tests to detect viral material:
– Those that detect the viral RMA, which is the genetic material of the virus. These test known as “PCR”, were the first to be used and are quite reliable PCR is a technology that expands the genetic material, making many copies what makes it possible to detect the viral material with very low viral load
– And during the month of September have became famous what are known as the “antigen tests” (they also came out at the beginning, but they were of low quality). These tests do not detect the genetic material but the structural proteins of the virus.

Serological tests should not be used to diagnose an infection because they do not detect the virus, what they detect is the reaction that the host has in the presence of an infection, that is, the antibodies that our body produces to defend itself against the infection and this occurs from the first moment but is not detectable until practically seven days after being infected. Therefore serological tests have limited utility to diagnose the infection, they serve to monitor the evolution and immunological status of the patient, if he is producing antibodies against the virus and how it evolves The virus remains elevated for months, but it does not mean that if you have had the disease and the rsults fo serological tests are negative, you are not prepared to face the virus, since we have memory cells that will surely produce antibodies again.

Cesar Fernández explains that the sample is the same in PCR and antigen tests, but the time it takes to obtain an answer is different. Both type of tests are recommended depending on the situation and the environment in which they are used, PCR tests have been used more massively and are more reliable in the sense that they let out much fewer positives, the number of false negatives they provide is very low, but they are also more expensive tests and need more time from the moment the sample is taken until the result is obtained (minimum 24 hours) since they are carried out in clinical analysis laboratories. The antigen tests can be carried out in 15-30 minutes in the place where the sample is taken and their cost is very low compared to that of the PCR, which is why they are very useful for screening studies of the levels infection that may exist in a community. Currently, work is being done on carrying out the antigen tests in saliva, this would facilitate the taking of samples and would not generate practically social rejection. Studies are also being done on the use of nasal smears in which the sample is taken at the beginning of the nasal cavity, resulting in much less annoying. Antigen tests due to their low cost and ease use open the possibility of performing in a very repetitive way.

Regarding the measurement of viral load, it is given by the PCR, while in the antigen tests the detection is visual, a colored line appears, similar to the pregnancy tests, with greater or lesser intensity, with which the information they give on viral load is semi-quantitative, that is, the interpretation is quite subjective.
The viral load of the disease appears a few days before sinthoms are shown (the peak is two days before) and can be spread to other people. This also occurs with asymptomatic infected people, with the only difference that, after this peak, the viral load falls very quickly and the disease does not appear.

Read More

New updated version of the CSIC report on COVID-19

The report by Spanish Higher Council for Scientific Research (CSIC) summarizng the most relevant scientific results on the Covid-19 pandemic.  “A global vision of the Covid-19 pandemic: What we know and what we are investigating from CSIC”, has just published its version number 4.

This report is structured in five blocks: prevention, disease, containment and diagnosis, treatment and vaccines, and global impact.

The containment and diagnosis block describes how the virus is transmitted in the air indoors and the analysis of wastewater as a system for early detection of SARS-CoV-2 is explained. In addition, the importance of diagnosis in the face of the pandemic is underlined and the different types of detection tests available and the diagnostic strategies to control the spread of the infection are detailed. The CIBER-BBN/IQAC-CSIC Nb4D research group and its research platform NANBIOSIS-ICTS Unit 2 Custom Antibody Service (CAbS) takes and important role in this block.

Pilar Marco, Scientific Director of CAbS is co-author, toguether with Cesar Fernandez (IBM-CNM-CSIC) of the chapter 3.4 “The role of the Diagnosis in the face of pandemic” wich provides information on the types of tests, how to perform and how to use them for the different purposes for which  diagnosis is an indispensable tool. “From a broad perspective, we can  distinguish between two types of tests: A. Viral tests: they detect the SARS-CoV-2 virus, include the well-known PCR (Polymerase Chain Reaction) or molecular tests, which detect the genetic material virus B. Test that detect the response of the human body to infection. They include so-called “serological tests, which detect antibodies produced by the patient’s immune system, although other types of biomarkers can also be detected.”

For further information and access to report: http://hdl.handle.net/10261/218312 

Read More

NANBIOSIS Expertise in the IQAC-CSIC Symposium dedicated to the fight against Covid-19 Pandemic

The 4th Annual IQAC Symposium will take place on September 23, 2020. This year will be dedicated to the research projects on COVID-19 that are being carried out in the IQAC-CSIC. It will be a dissemination day aiming to inform the general public about some of the lines of research that are currently being developed in the fight against the COVID-19 pandemic.

The event will be live streamed in Facebook: facebook.com/iqac.csic.es/

Three of the speakers, members of CIBER-BBN NANBIOSIS units at IQAC-CSIC, will explain their work. Pilar Marco and Roger Galve (NANBIOSIS U2 Custom Antibody Service (CAbS) will talk about “Wearable Devices for Detection rapid SARS-CoV-2” and Miriam Royo (NANBIOSIS U3 Synthesis of Peptides Unit shall inform about “Peptide-based chemical tools as diagnostic and therapeutic agents of COVID-19″

Further information and program: http://bit.ly/2ZLVT0o

The Institute for Advanced Chemistry of Catalonia (IQAC) is one of the research centers of the Spanish National Research Council (CSIC). The Institute is located in Barcelona and it was created in 2007 with the mission to perform research of excellence in Chemical Sciences with the broad goal of improving the quality of life. The research developed at IQAC is organized around two main nodes: Biological Chemistry and Nanobiotechnology, many of the investigations carried out by the Research Groups at IQAC lie at the intersection between nodes.

Since 2007 CIBER-BBN and IQAC-CSIC have created four Units of equipment and resources for research wich are part of NANBIOSIS and have been recognized by Spanish Goverment as ICTS (scientific and technical infrastructures, unique in its kind, that are dedicated to high quality research and technological development). The other two units Besides U2 an U3 are: U12 Nanostructured liquid characterization unit, led by Prof. Carlos Rodriguez Abreu and Unir29 Oligonucleotide Synthesis Platform (OSP), led by Prof. Ramón Eritja.

One on the projects in which NANBIOSIS units at CSIC are working in the fight against COVID-19 is CSIC POC4CoV project to develop diagnostic technologies for SARS-COV-2 in which participate 3 of our Units.

Read More